MAP2K7 and acute lymphoblastic leukemia: A recent report revealed that ALL samples with KRAS mutation are sensitive to inhibitors of MAP kinases in vitro.33 Thus, we tested sensitivity of t(17;19)‐ALL cell lines to selumetinib, a MEK inhibitor that has been reported to be active against ALL with the KRAS mutation.